Castro Jose G, Chin-Beckford Nafeesa
a 1 Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine , Miami, FL, USA.
b 2 Clinical Research Building , 1120 NW 14th Street, Suite 857, Miami, FL 33136, USA.
Expert Rev Clin Pharmacol. 2015;8(6):683-90. doi: 10.1586/17512433.2015.1082424. Epub 2015 Aug 27.
Chronic diarrhea remains a common condition that affects people infected with human immunodeficiency virus (HIV) despite the widespread use of potent antiretroviral therapy. It is important that providers control this condition, as the persistence of diarrhea affects the quality of life of patients and may contribute to decreased adherence to antiretroviral therapy. Strategies to control diarrhea in patients with HIV infection include switching to a new antiretroviral regimen and/or the use of specific medications to control the diarrhea. This review aims to provide a concise evaluation of a newly approved medication (crofelemer) that has a novel mechanism of action and has received approval for the symptomatic relief of non-infectious diarrhea in adult patients with HIV on anti-retroviral therapy.
尽管强效抗逆转录病毒疗法已广泛应用，但慢性腹泻仍是感染人类免疫缺陷病毒（HIV）的人群中常见的病症。医疗服务提供者控制这种病症很重要，因为腹泻持续会影响患者的生活质量，并可能导致对抗逆转录病毒疗法的依从性降低。控制HIV感染患者腹泻的策略包括换用新的抗逆转录病毒治疗方案和/或使用特定药物来控制腹泻。本综述旨在对一种新批准的药物（克罗felemer）进行简要评估，该药物具有新颖的作用机制，已获批用于缓解接受抗逆转录病毒治疗的成年HIV患者的非感染性腹泻症状。
